In an initial investigation, plasma p-tau217+Janssen was shown to exhibit good technical performance, discriminate accurately between AD and controls, and detect Aβ-positive and CSF p-tau-positive participants [22]. The gene discussed is MAPT; the disease is Alzheimer disease.